Insider Selling: Elevance Health (NYSE:ELV) EVP Sells 1,300 Shares of Company Stock

Elevance Health, Inc. (NYSE:ELV) EVP Ratnakar Lavu sold 1,300 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president owned 14,849 shares in the company, valued at $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Elevance Health Price Performance

NYSE:ELV traded down $5.83 during mid-day trading on Friday, hitting $426.17. 1,443,875 shares of the company’s stock traded hands, compared to its average volume of 1,597,887. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. The firm’s 50 day simple moving average is $412.38 and its 200 day simple moving average is $373.28. Elevance Health, Inc. has a 1 year low of $274.84 and a 1 year high of $450.69. The company has a market cap of $92.08 billion, a PE ratio of 18.17, a price-to-earnings-growth ratio of 2.07 and a beta of 0.63.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. During the same quarter in the previous year, the business posted $6.03 earnings per share. The firm’s quarterly revenue was up .7% compared to the same quarter last year. Sell-side analysts expect that Elevance Health, Inc. will post 29.16 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s payout ratio is currently 29.34%.

Hedge Funds Weigh In On Elevance Health

Several institutional investors have recently added to or reduced their stakes in ELV. Allworth Financial LP grew its holdings in Elevance Health by 11.0% in the 3rd quarter. Allworth Financial LP now owns 2,222 shares of the company’s stock valued at $859,000 after buying an additional 220 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Elevance Health by 3.0% during the 3rd quarter. Fisher Asset Management LLC now owns 1,660 shares of the company’s stock worth $646,000 after acquiring an additional 49 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Elevance Health by 20.9% in the third quarter. Russell Investments Group Ltd. now owns 671,321 shares of the company’s stock worth $261,442,000 after acquiring an additional 116,000 shares during the last quarter. Eurizon Capital SGR S.p.A. boosted its position in shares of Elevance Health by 150.2% in the third quarter. Eurizon Capital SGR S.p.A. now owns 168,509 shares of the company’s stock worth $65,714,000 after acquiring an additional 101,158 shares during the last quarter. Finally, Fifth Third Bancorp boosted its position in shares of Elevance Health by 16.4% in the third quarter. Fifth Third Bancorp now owns 46,558 shares of the company’s stock worth $18,103,000 after acquiring an additional 6,565 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELV has been the topic of a number of analyst reports. Morgan Stanley increased their target price on Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a report on Thursday, October 22nd. Leerink Partners raised their price target on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research report on Friday, July 17th. TD Cowen lifted their price target on shares of Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a report on Friday, October 23rd. Robert W. Baird boosted their price objective on shares of Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a research report on Thursday, October 22nd. Finally, Wells Fargo & Company boosted their price objective on shares of Elevance Health from $473.00 to $492.00 and gave the company an “overweight” rating in a research report on Tuesday, October 27th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $456.48.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

About Elevance Health

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.